Finasteride and HCG Interaction: Monitor | Peptide Database

Winlevi (clascoterone cream 1%) is FDA-approved for the topical treatment of acne vulgaris in patients 12 years and older. Phase 3 trials demonstrated statistically significant reductions in inflammatory and non-inflammatory lesion counts compared to vehicle, with an Investigator Global Assessment success rate significantly higher than placebo. Particularly relevant for women with androgen-driven acne who cannot tolerate or prefer to avoid systemic anti-androgens like spironolactone. Provides targeted anti-androgen activity at the sebaceous gland without the systemic effects, menstrual irregularities, or contraindication in pregnancy associated with oral anti-androgens. Breezula (clascoterone solution 7.5%) has completed Phase 3 clinical trials for androgenetic alopecia in men. Trial results showed improvements in target area hair count compared to vehicle. Regulatory submission is pending. The topical anti-androgen approach offers a potential alternative to systemic 5-alpha reductase inhibitors for men concerned about systemic side effects. The favorable safety profile and lack of systemic anti-androgenic effects make clascoterone a candidate for female androgenetic alopecia, where systemic anti-androgens carry teratogenic risks. Clinical data in women for this indication is still being developed.

First-line treatment for elevated LDL cholesterol and mixed dyslipidemia. Rosuvastatin 10-20 mg achieves LDL reductions of 45-55%, outperforming equivalent doses of other statins. Particularly appropriate when aggressive LDL lowering is required or when patients have not reached lipid targets on less potent statins. Widely used off-label to manage lipid disturbances caused by anabolic steroid cycles, especially oral AAS (oxandrolone, stanozolol, methandrostenolone) that severely impact lipid profiles. Typical on-cycle doses of 5-10 mg daily can meaningfully reduce LDL elevation, though HDL suppression caused by androgens is only partially mitigated. Most effective when started before or at the beginning of a cycle rather than reactively. Proven to reduce major cardiovascular events including myocardial infarction, stroke, and cardiovascular death. The JUPITER trial showed a 44% reduction in major cardiovascular events in apparently healthy individuals with elevated hsCRP. Particularly relevant for long-term AAS users who accumulate cardiovascular risk over time. Indicated for cardiovascular risk reduction in individuals without established cardiovascular disease but with risk factors such as dyslipidemia, family history, or elevated inflammatory markers. The JUPITER trial established benefit even in patients with LDL below 130 mg/dL if hsCRP was elevated above 2 mg/L. The METEOR trial demonstrated that rosuvastatin 40 mg significantly slowed progression of carotid intima-media thickness compared to placebo in low-risk patients with subclinical atherosclerosis. Suggests benefit in slowing vascular damage that may accumulate in chronic AAS users.